VCM
ALXN

Vision Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Vision Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,185
Closed -$2.06M – 107
2020
Q4 		$2.06M Buy
13,185
+311
+2% +$40K 0.38% 54
2020
Q3 		$1.47M Sell
12,874
-67
-0.5% -$7.23K 0.31% 62
2020
Q2 		$1.45M Sell
12,941
-694
-5% -$73.7K 0.33% 60
2020
Q1 		$1.22M Buy
13,635
+3,177
+30% +$312K 0.33% 53
2019
Q4 		$1.13M Sell
10,458
-5,678
-35% -$607K 0.26% 58
2019
Q3 		$1.58M Buy
16,136
+5,654
+54% +$637K 0.41% 50
2019
Q2 		$1.37M Buy
10,482
+113
+1% +$14.6K 0.36% 51
2019
Q1 		$1.4M Buy
+10,369
New +$1.29M 0.39% 51
2015
Q2 		– Sell
-62,648
Closed -$10.9M – 70
2015
Q1 		$10.9M Sell
62,648
-19,712
-24% -$3.57M 1.63% 37
2014
Q4 		$15.2M Buy
82,360
+3,647
+5% +$676K 1.75% 38
2014
Q3 		$13.1M Sell
78,713
-3,983
-5% -$654K 1.62% 38
2014
Q2 		$12.9M Sell
82,696
-42,813
-34% -$6.76M 1.54% 40
2014
Q1 		$19.1M Sell
125,509
-4,410
-3% -$701K 2.33% 28
2013
Q4 		$17.3M Buy
129,919
+3,810
+3% +$457K 2.05% 38
2013
Q3 		$14.6M Buy
126,109
+29,409
+30% +$3.23M 1.73% 40
2013
Q2 		$8.92M Buy
+96,700
New +$9.32M 1.43% 40

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vision Capital Management's ALXN Position: Q1 2021 in Review

Vision Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 13,185 shares — an estimated $2.06M sold.

Vision Capital Management first reported a position in ALXN in Q2 2013 and held it in 16 quarters. The position peaked at $19.1M in Q1 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Vision Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vision Capital Management sold 13,185 Alexion Pharmaceuticals shares in Q1 2021, an estimated $2.06M.
  • Vision Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Vision Capital Management's Alexion Pharmaceuticals position peaked at $19.1M in Q1 2014.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Vision Capital Management's 13F filing for Q1 2021, filed 21 Apr 2021.